Advantages of RNA in oncology R&D: Genialis’ CEO joins Tempus’ webinar
At the end of May, Genialis CEO Rafael Rosengarten, [...]
Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA-based patient classifier
KRAS mutations are among the most prevalent oncogenic drivers [...]
Precision medicine is our future and our fate | TPM podcast #46
Tempus’ live webinar featuring Rafael Rosengarten [...]
Genialis Highlights Power of its Supermodel to Predict and Explain Therapeutic Response at AACR 2025
New results from translational, clinical, and real-world studies showcase [...]
On a mission to beat an ignoble killer: pancreatic cancer | TPM podcast #45
Schedule a meeting Genialis™ Supermodel - [...]
Genialis™ Supermodel: Predicting monotherapy and combination therapy responses in KRAS-mutated cancers using a large molecular model of cancer biology
KRAS mutations drive approximately 25% of human cancers, resulting [...]
Biology-driven, machine learning-based development of a biomarker to predict response to WEE1 inhibitor Debio 0123
The WEE1 kinase is a central regulator of G2/M [...]
Highlights from Fireside Chat with Rafael Rosengarten
"In cancer treatment, a simple yes or no isn’t [...]
Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM podcast #44
Genialis’ Upcoming Events Genialis on LinkedIn [...]
Data-driven cancer care: Luka Ausec on the Faces of Digital Health podcast
Genialis’ Chief Discovery Officer, Luka Ausec, recently joined Tjaša [...]
